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Introduction
It is well known that dietary sodium restriction 
lowers blood pressure and can prevent hyper-
tension. Many observational studies have shown a 
close correlation between sodium intake and blood 
pressure1, 2). Meta-analyses of randomized trials 
of sodium restriction in people with and without 
hypertension have supported these observational 
findings3, 4). Recent evidence suggests that long-
term interventions aimed at reduction of sodium 
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ABSTRACT
Background: Both subtle elevation of B-type natriuretic peptide (BNP) and a decrease in estimated 
glomerular filtration ratio (eGFR) were reported to be related to the development of cardiovascular 
disease in apparently asymptomatic populations. However, the relationship between excess salt 
intake, eGFR and BNP in the general population remains to be determined.
Methods and Results: This community-based cross sectional study enrolled individuals over 40 
years old (n = 3115) in Takahata, Japan. There were 206 subjects with chronic kidney disease (CKD) 
(eGFR < 60 mL/min/1.73m2). Plasma BNP levels were higher in subjects with CKD than in those 
without CKD. However, subjects with CKD had a lower salt intake, higher systolic blood pressure 
and higher plasma renin activity (PRA) than subjects without CKD. There was a greater increase in 
BNP levels with salt intake in CKD subjects compared to those without CKD. PRA was significantly 
suppressed by excess salt intake in both groups. Multivariate analysis showed that salt intake was 
an independent risk factor for elevated BNP levels in CKD subjects, but not in those without CKD. 
Conclusions: Excess salt intake is an independent risk factor for elevated plasma BNP levels, 
especially in subjects with CKD. These results suggest that sodium restriction for prevention of 
future cardiovascular events may be more important in subjects with CKD than in those without 
CKD.
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 blood pressure
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intake may reduce the risk of cardiovascular 
disease (CVD) 5, 6).
  A graded association between glomerular 
filtration rate (GFR) and cardiovascular deaths was 
demonstrated with a subtle decrease in GFR (<60-80 
mL/min/1.73m2), which increased the independent 
risk of death, acute cardiovascular events, 
hospitalization and cardiovascular complications 
following myocardial infarction7, 8). Even micro-
albuminuria, in the absence of an apparent decrease 
in renal function or diabetes mellitus, is a predictor 
for CVD and death9).
  Increased salt intake elevates systemic and 
glomerular pressure and increases the risk of 
adverse renal events such as proteinuria, absence 
of nocturnal decrease in blood pressure with 
decrease in renal function, and end stage renal 
dysfunction10). 
  Plasma B-type natriuretic peptide (BNP) levels 
are extremely low in healthy individuals. Plasma 
BNP is an important marker for heart failure 
in clinical practice, because BNP levels increase 
in early stage heart failure before the onset of 
symptoms, and also reflect disease severity. The 
measurement of plasma BNP levels has important 
implications for assessing the condition of patients 
with heart failure11, 12). 
  Heart-type fatty acid-binding protein (H-FABP) 
is a low molecular weight (14-15 kDa) cytoplasmic 
protein involved in the transport of long-chain 
fatty acids in cardiomyocytes. H-FABP is rapidly 
released into the circulation when the myocardium 
is injured. We and others have demonstrated 
that H-FABP is a promising marker for latent 
myocardial damage and the prognosis of patients 
with chronic heart failure13, 14). 
  There have been a few reports on the impact 
of salt intake on plasma BNP levels in subjects 
with chronic kidney disease (CKD). Excess salt 
intake was shown to cause hypertension, renal 
dysfunction and myocardial injury15-17). In addition, 
plasma BNP levels were not increased after 
short-term sodium loading in healthy subjects18). 
However, little is known about the relationship 
between long-term excess salt intake and plasma 
BNP levels in the general population. In the present 
study, we investigated the impact of excess salt 
intake on plasma BNP levels and H-FABP levels in 
a general population with CKD.
Methods
Study population
This study was part of the ongoing molecular 
epidemiological study utilizing the regional 
characteristics of the 21st Century Center 
of Excellence (COE) program and the global 
COE program in Japan. Details of the study 
methodology have been described elsewhere19).
  The survey population for this community-based 
study was the general population, aged 40 to 87 
years, of Takahata town (total population 26,026) 
in northern Japan. This region has a resident 
population of 15,222 adults over the age of 40 years 
(7,109 men, 8,113 women). From June 2004 through 
November 2005, 1,394 men and 1,771 women (a 
total of 3,165 subjects) agreed to participate in the 
study. The total participation rate was 20.5% (19.4% 
of men, 21.4% of women). The study was approved 
by the institutional ethics committee and all 
participants gave written informed consent. Fifty 
subjects were excluded from the present analysis 
because of incomplete data. In total, 3,115 subjects 
were entered into the final statistical analysis. 
There were 1,380 men (44.3%) and 1,735 women 
(55.7%). The mean age was 63 years.
Measurements
A self-report questionnaire was used to document 
medical history, current medications and clinical 
symptoms. Systolic and diastolic blood pressures 
were measured using a mercury manometer, with 
the subject in a sitting position after at least 5 
min of rest. Hypertension was defined as a systolic 
blood pressure ≥140 mm Hg and/or diastolic 
blood pressure ≥90 mm Hg and/or the use of anti-
hypertensive medication. Diabetes mellitus was 
confirmed either by self-reported physical diagnosis 
or by a fasting plasma glucose level >126 mg/dL or 
a HbA1c (JDS) value ≥6.5%. Hypercholesterolemia 
was confirmed by a serum total cholesterol 
concentration ≥220 mg/dL and/or the use of anti-
hyperlipidemic medication. The urine albumin-
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creatinine ratio (UACR) was measured in a single 
spot urine specimen collected in the early morning. 
The urine albumin concentration was determined 
by immunoturbidimetry. Albuminuria was defined 
as UACR >30 mg/g･Cr. CKD was defined as an 
estimated GFR (eGFR) <60 mL/min/1.73m2.
  Serum creatinine (SCr) was measured by an 
enzymatic method. The GFR was estimated using 
the Japanese version of the equation used in the 
Modification of Diet in Renal Disease (MDRD) 
study (20). Salt intake was estimated from a single 
urine sample, using the formula of Kawasaki: 24 
h urinary Na (mEq/day) = 16.3 square root of XNa, 
where XNa = second morning voiding urine (SMU)Na 
/SMUCr x predicted 24 h urinary Cr excretion
21).
  Plasma BNP concentrations were measured 
u s i n g  a  c o m m e r c i a l l y  a v a i l a b l e  s p e c i f i c 
radioimmunoassay for human BNP (Shiono RIA 
BNP assay kit, Shionogi Co. Ltd., Tokyo, Japan). 
The analytical range of the assay was 4-2000 pg/
mL. H-FABP levels were measured using a two-
step sandwich enzyme-linked immunosorbent assay 
(ELISA) kit (MARKIT-M H-FABP, Dainippon 
Pharmaceutical Co Ltd, Tokyo, Japan). The cut-off 
value for BNP was determined as the mean + 1 SD, 
which was 78.8 pg/mL22). 
Statistical analyses
Student’s t-test was used to evaluate the significance 
of differences in mean values and chi-square test 
was used to evaluate differences in proportions. 
The non-parametric Mann-Whitney U-test and 
Kruskal-Wallis test were used for parameters that 
were not normally distributed. Study participants 
were divided into two groups: the CKD group and 
those without CKD. The influence of salt intake 
on plasma BNP levels was analyzed in each group. 
Logistic regression analysis was performed to 
identify independent predictors of high BNP level 
in the general population. Variables identified as 
significant in the univariate analysis were entered 
into the multivariate analysis. Data are expressed 
as mean ± SD. A significant difference was defined 
as P <0.05.
Results
The characteristics of the study subjects are shown 
in Table 1. There were 206 subjects with CKD 
Table 1. Comparison of characteristics between non-CKD subjects and CKD subjects
All Non-CKD CKD p value
n 3115
63.0 ± 10.3
1380 (44.3)
23.5 ± 3.2
12.4 ± 3.4
134.2 ± 15.9
79.3 ± 10.0
4.5 ± 0.3
0.68 ± 0.22
1042 (33.5)
240 (7.7)
13.7 ± 1.5
9.3 (6.0, 18.3)
9.75 (5.06, 22.6)
81.3 ± 16.4
5.1 ± 1.4
0.9 (0.4, 1.8)
14.8 ± 5.1
19.0 (10.3, 34.5)
3.4 (2.6, 4.5)
2909
62.5 ± 10.1
1279 (44.0)
23.5 ± 3.2
12.6 ± 3.4
133.9 ± 15.9
79.2 ± 10.1
4.5 ± 0.3
0.65 ± 0.13
972 (33.4)
212 (7.3)
13.7 ± 1.4
9.1 (5.9, 17.5)
9.62 (5.04, 21.8)
83.4 ± 14.7
5.0 ± 1.3
0.8 (0.4, 1.7)
14.8 ± 5.1
18.6 (10.1, 33.5)
3.3 (2.5, 4.3)
206
70.8 ± 8.5
101 (49.0)
24.1 ± 3.5
10.6 ± 3.0
138.8 ± 14.8
79.9 ± 9.7
4.5 ± 0.3
1.04 ± 0.61
70 (34.0)
28 (13.6)
13.5 ± 1.6
14.9 (7.1, 51.5)
13.63 (5.71, 55.3)
51.4 ± 8.3
6.0 ± 1.5
1.2 (0.4, 2.7)
14.7 ± 5.9
28.7 (14.6, 66.9)
5.6 (4.1, 7.0)
-
<0.05
<0.05
<0.05
<0.05
<0.05
N.S.
N.S.
<0.05
N.S.
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
N.S.
<0.05
<0.05
Age (years)
Male, N (%)
BMI (kg/m2)
Salt intake (g/day)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Serum albumin (g/dl)
SCr (mg/dl)
HL, N (%)
DM, N (%)
Hemoglobin (g/dl)
Albuminuria (mg)
UACR (mg/g)
eGFR (ml/min/1.73 m2)
Uric acid (mg/dl)
PRA (ng/ml/h)
ACE (IU/L)
BNP (pg/ml) 
H-FABP (ng/ml)
Nonparametric variables are expressed as median with range (25th, 75th)
CKD, chronic kidney disease; BMI, body mass index; BP, blood pressure; SCr, serum creatinin; HL, hyperlipidemia; DM, 
diabetes mellitus; UACR, urine albumin-creatinine ratio; eGFR, estimated glomerular filtration ratio; PRA, plasma 
renin activity; ACE, angiotensin converting enzyme; BNP, brain natriuretic peptide; H-FABP, heart type fatty acid 
binding protein.
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among the 3,115 participants. Both non-CKD and 
CKD subject were divided into two subgroups 
based on BNP levels (Table 2). The CKD subjects 
with high BNP were older and had a higher salt 
intake, lower total protein, lower hemoglobin 
concentration, lower plasma renin activity (PRA) 
and higher prevalence of albuminuria compared 
to those with low BNP. However, there was no 
difference of salt intake between non-CKD subjects 
with low or high BNP levels.
Salt intake in subjects with CKD
Participants were divided into three groups based 
on their eGFR (≥90, 60-89, <60 mL/min/1.73m2). 
As shown in Figure 1, plasma BNP levels increased 
with increasing salt intake in CKD subjects, 
whereas excess salt intake had less influence 
on plasma BNP levels in subjects without CKD. 
Univariate logistic regression analysis showed that 
increased age, low total protein, low low-density 
Table 2. Comparison of characteristics between non-CKD subjects and CKD subjects with low or high BNP
All Non CKD CKD
　　　　　　　　BNP Low High Low High Low High
n 2914
62.4±10.2
1284(44.1)
23.5±3.2
12.4±3.4
1573(54.0)
133.9±15.8
79.2±10.0
7.5±0.4
4.5±0.2
1110(38.1)
220(7.5)
13.7±1.4
164(5.6)
27.6±93.6
9.4(4.9,21.2)
0.7±0.2
81.8±16.1
5.0±1.3
0.9(0.4,1.8)
14.8±5.1
17.7(9.8,30.4)
3.3(2.5,4.4)
90(3.1)
201
71.3±7.8‡
96(47.8)
23.2±3.5
12.6±3.8
145(72.1)
138.5±16.4‡
80.0±10.5
7.3±0.5‡
4.4±0.4‡
55(27.4)†
20(10.0)
13.2±1.7‡
42(20.9)‡
96.3±430.3‡
19.5(8.1,59.6)‡
0.8±0.6‡
73.4±19.2‡
5.3±1.5†
0.6(0.3,1.1)†
15.0±6.2
111.4(88.8,162.1)‡
4.3(3.4,5.9)‡
15(7.5)‡
2750
62.0±10.1
1204(43.8)
23.5±3.2
12.5±3.4
1452(52.8)
133.7±15.9
79.2±10.1
7.5±0.4
4.5±0.2
1043(37.9)
201(7.3)
13.8±1.4
-
25.0±84.0
9.4(4.9,20.8)
0.6±0.1
83.5±14.8
5.0±1.3
0.9(0.4,1.7)
14.8±5.0
17.6(9.6,30.1)
3.3(2.5,4.3)
84(3.1)
159
70.2±7.9‡
75(47.2)
23.1±3.5
12.8±3.8
108(67.9)‡
138.1±16.0‡
80.2±10.4
7.3±0.5‡
4.4±0.3‡
43(27.0)†
11(6.9)
13.4±1.6†
-
40.0±101.9†
17.0(7.6,46.2)‡
0.7±0.1
80.6±13.8†
5.1±1.4
0.6(0.3,1.0)†
15.1±5.8
107.8(87,147.1)‡
4.0(3.2,5.1)‡
13(8.2)‡
164
69.6±8.7
80(48.8)
24.2±3.4
10.3±2.8
121(73.8)
138.5±14.0
80.0±9.3
7.6±0.4
4.5±0.3
67(40.9)
19(11.6)
13.7±1.4
-
71.8±188.5
10.5(5.3,36)
1.0±0.2
52.7±6.8
6.0±1.5
1.5(0.5,2.9)
14.6±5.5
23.3(11.5,35.1)
5.3(3.8,6.7)
6(3.7)
42
75.5±5.3‡
21(50.0)
23.7±3.6
11.8±3.8†
37(88.1)
139.9±18.0
79.4±11.1
7.2±0.6‡
4.4±0.4†
12(28.6)
9(21.4)
12.6±1.9‡
-
309.2±896.9†
51.4(14.7,205)‡
1.3±1.2†
46.5±11.6‡
6.2±1.4
0.7(0.2,1.6)†
14.9±7.4
141.1(107.5,196.8)‡
6.5(4.9,8.4)‡
2(4.8)
Age(years)
Men,N(%)
BMI(kg/m2)
Saltintake(g/day)
HT,N(%)
　SystolicBP(mmHg)
　DiastolicBP(mmHg)
Totalprotein(g/dl)
Serumalbumin(g/dl)
HL,N(%)
DM,N(%)
Hemoglobin(g/dl)
CKD,N(%)
　Albuminuria(mg/day)
　UACR(mg/g･Cr)
　SCr(mg/dl)
　eGFR(ml/min/1.73m2)
Uricacid(mg/dl)
PRA(ng/ml/h)
ACE(IU/L)
BNP(pg/ml)
H-FABP(ng/ml)
PriorCVDepisode,N(%)
Non normal distribution variables are expressed as median with range (25th, 75th)
BMI, body mass index; HT, hypertension; BP, blood pressure; HL, hyperlipidemia; DM, diabetes mellitus; CKD, chronic 
kidney disease; UACR, urine albumin-creatinine ratio; SCr, serum creatinine; eGFR, estimated glomerular filtration ratio; 
PRA, plasma renin activity; ACE, angiotensin converting enzyme; BNP, brain natriuretic peptide; H-FABP, heart type 
fatty acid binding protein; CVD, cardio vascular disease; † , P<0.05 vs. subject with low BNP; ‡ , P<0.001 vs. subject with 
low BNP.
Figure1. Excess salt intake increased plasma BNP 
levels in subjects with CKD. 
Abbreviations are as indicated in Table 1. A box 
plot displays the median, quartiles, and 10%tile and 
90%tile observation for each group. Kruskal Wallis 
was used to evaluate differences.
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lipoprotein (LDL) cholesterol and low hemoglobin 
concentrations, low eGFR, albuminuria, and high 
salt intake were significantly associated with high 
plasma BNP levels in CKD subjects (Table 3). In 
the case of subjects without CKD, increased age, 
high systolic blood pressure, low total protein and 
LDL cholesterol concentrations, and hemoglobin 
concentrations, low PRA, low eGFR, and high 
prevalence of albuminuria were associated with 
high BNP levels. Prior CVD history was associated 
with high plasma BNP levels in subjects without 
CKD but not CKD subjects.
  Multivariate logistic regression analysis showed 
that low serum total protein concentration, 
increased age, albuminuria and high salt intake 
were independently associated with high plasma 
levels of BNP in CKD subjects (Table 4). The odds 
ratio for the association between a 5 g per day 
increase in salt intake and high BNP levels was 1.92 
(95%C.I., 1.00-3.86). On the other hand, in subjects 
without CKD, increased age, low total protein 
and low LDL cholesterol concentrations, low PRA 
Table 3. Univariate logistic regression analysis for high plasma BNP levels in non-CKD and CKD subjects
Non-CKD CKD
OR 95% CI p value OR 95% CI p value
Age (per 10 years increase) 2.61 2.16-3.11 <0.001 2.86 1.63-4.81 <0.001
Gender (men) 1.15 0.83-1.58 0.403 1.05 0.53-2.07 0.888
Salt intake (per 5 g/day increase) 1.11 0.86-1.40 0.387 2.23 1.28-4.01 0.006
BMI (per 1 increase) 0.97 0.92-1.02 0.175 0.95 0.86-1.05 0.321
Systolic BP (per 10 mmHg increase) 1.22 1.10-1.34 <0.001 1.11 0.82-1.34 0.583
Diastolic BP (per 10 mmHg increase) 1.11 0.90-1.34 0.225 0.91 0.66-1.34 0.722
Total protein (per 1SD increase) 0.68 0.58-0.80 <0.001 0.42 0.28-0.64 <0.001
Uric acid (per 1SD increase) 1.13 0.96-1.31 0.147 1.11 0.79-1.54 0.570
LDL-C (per 1SD increase) 0.75 0.55-0.74 <0.001 0.55 0.40-0.74 0.005
Hemoglobin (per 1g/dl increase) 0.84 0.75-0.93 0.001 0.62 0.49-0.79 <0.001
eGFR (per 10 ml/min/1.73m2 increase) 0.91 0.74-1.00 0.013 0.45 0.31-0.66 <0.001
PRA (per 1 increase) 0.73 0.62-0.87 <0.001 0.85 0.71-1.02 0.080
Current smoking 0.86 0.61-1.23 0.413 1.22 0.58-2.56 0.594
Albuminuria 1.88 1.32-2.69 <0.001 3.77 1.87-7.63 <0.001
Prior CVD episode 2.85 1.55-5.23   <0.001 1.32 0.26-6.77 0.742
LDL-C, low-density lipoprotein cholesterol; other abbreviations as in Table 2
Table 4.  Multivariate logistic regression analysis for high plasma BNP levels in non-CKD and CKD subjects
non-CKD subjects Odd Ratio 95% CI p value
Age (per 10 years increase) 2.44 1.95-3.02 <0.001
Systolic BP (per 10 mmHg increase) 1.08 0.97-1.22 0.163
Total protein (per 1SD increase) 0.73 0.61-0.88 <0.001
LDL-C (per 1SD increase) 0.79 0.66-0.94 0.008
Hemoglobin (per 1 g/dl increase) 0.96 0.85-1.10 0.571
eGFR (per 10 ml/min/1.73m2 increase) 0.94 0.83-1.06 0.348
PRA (per 1SD increase) 0.58 0.41-0.83 0.003
Albuminuria 1.48 1.00-2.18 0.047
Prior CVD episode 2.71 1.42-5.18 0.003
CKD subjects Odd Ratio 95% CI p value
Age (per 10 years increase) 2.27 1.34-4.81 0.005
Total protein (per 1SD increase) 0.56 0.36-0.87 0.010
LDL-C (per 1SD increase) 0.76 0.46-1.19 0.229
Hemoglobin (per 1 g/dl increase) 0.93 0.68-1.28 0.669
eGFR (per 10 ml/min/1.73m2 increase) 0.62 0.37-1.04 0.072
Albuminuria 2.59 1.09-6.15 0.031
Salt intake(per 5 g/day increase) 1.92 1.00-3.86 0.047
Abbreviations as in Table 2, 3.
－ 12 －
Tamabuchi, Watanabe, Konta, Tamura, Nishiyama, Arimoto, Takahashi, Shishido, Miyashita, Miyamoto, Shibata, Ueno, Kato, Fukao, Kayama, Kubota
and albuminuria, but not high salt intake, were 
independent risk factors for high BNP levels (Table 
4). CKD subjects with an excess salt intake had a 
higher prevalence of hypertension, higher UACR 
and lower PRA than those with a moderate salt 
intake (Table 5). There were greater increases in 
plasma BNP levels in CKD subjects with an excess 
salt intake (>15 g/day) compared to those with a 
moderate salt intake (≤15 g/day).
  Figure 2 shows that BNP and H-FABP increased 
with advancing renal dysfunction. CKD subjects 
with an excess salt intake showed a greater 
increase in BNP levels than those with a moderate 
salt intake, while excess salt intake did not alter 
BNP levels in subjects without CKD (Figure 2A). 
CKD subjects with an excess salt intake showed a 
slight but not significant increase in H-FABP levels 
compared to those with a moderate salt intake 
(Figure 2B).
Table 5. Characteristics of 3 CKD groups based on amount of salt intake
Salt intake
All < 10 g/day 10-15 g/day > 15 g/day P value
n 206
70.8 ± 8.5
24.1 ± 3.5
10.6 ± 3.0
158 (76.7)
139 ± 14.8
80 ± 9.7
79 (38.3)
28 (13.6)
1.04 ± 0.60
51.4 ± 8.3
13.6 (5.7, 55.3)
6.0 ± 1.4
1.2 (0.4, 2.7)
14.7 ± 5.9
28.7 (14.6, 66.9)
5.6 (4.1, 7.0)
8 (3.9)
90
71.4 ± 8.4
23.5 ± 3.5
7.9 ± 1.5
62 (68.9)
135 ± 13.1
78 ± 9.0
34 (37.8)
14 (15.6)
1.03 ± 0.58
51.0 ± 8.6
9.4 (4.6, 34.8)
6.1 ± 1.7
1.5 (0.7, 3.7)
14.8 ± 6.0
28.1 (15.2, 58.3)
5.3 (3.7, 7.0)
3 (3.3)
99
69.7 ± 8.8
24.7 ± 3.3
12.0 ± 1.4
79 (80.6)
141 ± 15.9
81 ± 9.5
42 (42.9)
12 (12.2)
1.04 ± 0.68
51.8 ± 8.5
16.4 (7.5, 99.5)
6.0 ± 1.2
1.1 (0.4, 2.3)
15.2 ± 5.3
27.2 (12.5, 65.7)
5.8 (4.1, 6.8)
4 (4.0)
17
72.9 ± 5.7
24.6 ± 3.4
16.6 ± 1.6
16 (94.1)
144 ± 12.7
84 ± 12.0
3 (17.6)
2 (11.8)
1.01 ± 0.17
52.2 ± 5.8
59.3 (10.4, 168.9)
5.9 ± 1.2
0.6 (0.3, 1.7)
12.0 ± 8.3
71.7 (24.2, 135.4)
6.3 (4.7, 7.6)
1 (5.9)
-
0.273
0.036
<0.001
0.034
0.005
0.024
0.140
0.782
0.475
0.667
0.007
0.915
0.007
0.288
0.036
0.277
0.878
Age (years)
BMI (m/kg2)
Salt intake (g/day)
HT, N (%)
　Systolic BP (mmHg)
　Diastolic BP (mmHg)
HL, N (%)
DM, N (%)
SCr (mg/dl)
eGFR (ml/min/1.73m2)
UACR (mg/g・Cr)
Uric acid (mg/dl)
PRA (ng/ml/h)
ACE (IU/L)
BNP (pg/ml)
H-FABP (ng/ml)
Prior CVD episode, N (%)
Nonparametric variables are expressed as median with range (25th, 75th). Abbreviations as in Table 2, 3
Figure 2. Excess salt intake induced greater myocardial damage in subjects with CKD. 
A) Impact of excess salt intake and eGFR on plasma BNP levels. B) Impact of excess salt intake and eGFR 
on serum H-FABP levels. Abbreviations are as indicated in Table 1; *p <0.05 vs. subject with salt intake 
<15g/day.
Impact of excess salt intake on BNP in CKD
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Discussion
Subjects with CKD had higher plasma BNP and 
serum H-FABP levels than subjects without CKD. 
Multivariate analysis revealed that salt intake was 
an independent risk factor for elevated BNP levels 
in CKD subjects but not those without CKD.
Excess salt consumption and hypertension
Although salt intake has recently decreased in 
Japan, it is still higher than that of other developed 
countries23). Average salt intake in Japan was 11.4 
g/day in men and 9.8 g/day in women according to 
the National Health and Nutrition Survey 200824). 
An intimate relationship between dietary salt and 
blood pressure was identified by the worldwide 
INTERSALT survey25), and increased dietary salt is 
known to have adverse effects on the cardiovascular 
system independently of blood pressure. As 
shown in Table 1, subjects with CKD had a higher 
prevalence of hypertension and a lower salt intake 
than those without CKD. Subjects with CKD and 
hypertension might be strongly recommended for 
sodium restriction by their doctors. It has also 
been reported that dietary salt intake is positively 
related to left ventricular mass26). Several studies 
showed the effects of dietary salt on cardiac 
damage independently of blood pressure27, 28). Many 
reports have suggested an optimal cut off value 
for BNP, for identification of heart disease, of 50 
to 130 pg/mL or greater22). In the present study, 
we determined the cut-off value for BNP as the 
mean + 1 SD, which was 78.8 pg/mL. There are 
many confounding factors influencing plasma 
BNP levels, including left ventricular wall stress, 
neurohumoral factors, aging, anemia, and renal 
disease. An excess salt intake was reported to 
increase circulating blood volume, blood pressure 
and high afterload, which increase BNP levels29). 
We observed a large impact of excess salt intake 
on plasma BNP levels in CKD subjects, but not 
in subjects without CKD (Figure 1). The CKD 
subjects may have high plasma BNP levels because 
of volume overload30) and low excretion of BNP31) 
as well as cardiac damage. Multivariate analysis 
revealed that excess salt intake was an independent 
risk factor for elevation of plasma BNP in CKD 
subjects. The odds ratio for elevation of BNP in 
CKD subjects was 1.92 per 5 g/day increase in 
salt intake. Surplus salt is adequately excreted by 
the kidney if renal function is normal; therefore 
subjects without CKD would not have high plasma 
BNP levels32).
Influence of salt intake on chronic kidney disease
There is  increasing evidence from animal 
experiments that salt increases reactive oxygen 
species within the vasculature and renal cortex, 
which may be associated with the development 
of interstitial fibrosis and progressive renal 
dysfunction33). As shown in Table 5, CKD subjects 
with an excess salt intake had greater UACRs 
than CKD subjects with a moderate salt intake. 
This result suggested that excess salt intake 
is probably associated with the development of 
microalbuminuria. 
Excess salt intake induces myocardial damage 
H-FABP is rapidly released into the circulation 
when the myocardium is injured34). We reported 
that H-FABP is a sensitive marker of ongoing 
myocardial damage35). We observed elevation 
of H-FABP, as well as plasma BNP levels, with 
decreasing eGFR (Figure 2B). The increase in 
H-FABP levels tended to be greater in CKD 
subjects with an excess salt intake than in those 
with a moderate salt intake, whereas there were 
no statistical significance between subjects with 
and without CKD because of limited number of 
CKD subjects. These results suggest that the 
impact of excess salt intake on left ventricular 
dysfunction and myocardial damage may be 
augmented by renal insufficiency. Animal 
experiments also showed that chronic salt loading 
or uninephrectomy caused myocardial damage36). 
Since BNP is a cardiac neurohormone that has 
cardioprotective effects such as vasodilatation, 
and suppression of renin-angiotensin aldosterone 
activation, sympathetic nerve activity and cardiac 
hypertrophy36, 37), BNP levels may increase in 
response to myocardial damage as well as volume 
overload resulting from excess salt intake. A 
previous study showed that plasma BNP levels 
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provided strong predictive information about the 
future onset of heart failure and mortality in the 
general population38). 
  In conclusions,  excess salt  intake is  an 
independent risk factor for elevated plasma BNP 
levels in subjects with CKD. Sodium restriction for 
prevention of future cardiovascular events may be 
more important in subjects with CKD than in those 
without CKD.
Limitations
There are limitations to this study. First, we did 
not measure aldosterone which is influenced by 
salt intake39). Second, detailed information about 
the types of anti-hypertensive drugs being used 
was not available. Some reports indicated that 
angiotensin converting enzyme inhibitors (ACE-I) 
and angiotensin II receptor blockers (ARB) increase 
plasma renin activity40). Administration of anti-
hypertensive drugs such as diuretics, ACE-I and 
ARB may influence sodium excretion. Third, poor 
medication compliance might be associated with 
elevation of BNP levels in subjects with CKD and 
hypertension who cannot obey sodium restriction 
diet. However, there were no data about medical 
compliance in the present study. Finally, since the 
salt sensitivity of the Japanese is relatively high41), 
salt sensitivity may have influenced the results of 
the present study. However, we did not assess salt 
sensitivity in this study. Further studies might be 
required to clarify the points.
Conclusion
Excess salt intake may augment myocardial 
damage in subjects with CKD. Optimal sodium 
restriction is required to prevent cardiovascular 
disease, especially in subjects with CKD.
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